These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 1455216)

  • 1. Left-handed comments.
    Brewster JH; Laskowski M
    Science; 1992 Nov; 258(5086):1289; author reply 1290. PubMed ID: 1455216
    [No Abstract]   [Full Text] [Related]  

  • 2. Investigating the stereochemistry of binding to HIV-1 protease with inhibitors containing isomers of 4-amino-3-hydroxy-5-phenylpentanoic acid.
    Raju B; Deshpande MS
    Biochem Biophys Res Commun; 1991 Oct; 180(1):187-90. PubMed ID: 1930215
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Total chemical synthesis of a D-enzyme: the enantiomers of HIV-1 protease show reciprocal chiral substrate specificity [corrected].
    Milton RC; Milton SC; Kent SB
    Science; 1992 Jun; 256(5062):1445-8. PubMed ID: 1604320
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIVdb: a database of the structures of human immunodeficiency virus protease.
    Vondrasek J; Wlodawer A
    Proteins; 2002 Dec; 49(4):429-31. PubMed ID: 12402352
    [No Abstract]   [Full Text] [Related]  

  • 5. Probing the S1/S1' substrate binding pocket geometry of HIV-1 protease with modified aspartic acid analogues.
    Short GF; Laikhter AL; Lodder M; Shayo Y; Arslan T; Hecht SM
    Biochemistry; 2000 Aug; 39(30):8768-81. PubMed ID: 10913288
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A heterologous substrate assay for the HIV-1 protease engineered in Escherichia coli.
    Stebbins J; Deckman IC; Richardson SB; Debouck C
    Anal Biochem; 1996 Nov; 242(1):90-4. PubMed ID: 8923970
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure-based inhibitors of HIV-1 protease.
    Wlodawer A; Erickson JW
    Annu Rev Biochem; 1993; 62():543-85. PubMed ID: 8352596
    [No Abstract]   [Full Text] [Related]  

  • 8. Comparative studies on inhibitors of HIV protease: a target for drug design.
    Jayaraman S; Shah K
    In Silico Biol; 2008; 8(5-6):427-47. PubMed ID: 19374129
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Switching between allosteric and dimerization inhibition of HIV-1 protease.
    Bowman MJ; Byrne S; Chmielewski J
    Chem Biol; 2005 Apr; 12(4):439-44. PubMed ID: 15850980
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anomalous adsorptive properties of HIV protease: indication of two-dimensional crystallization?
    Cígler P; Král V; Kozísek M; Konvalinka J; Mirsky VM
    Colloids Surf B Biointerfaces; 2008 Jun; 64(1):145-9. PubMed ID: 18304786
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Development of HIV protease inhibitors as anti AIDS drugs: molecular design based on substrate transition state].
    Kiso Y
    Tanpakushitsu Kakusan Koso; 1998 May; 43(6):725-33. PubMed ID: 9612066
    [No Abstract]   [Full Text] [Related]  

  • 12. Pentacycloundecane-based inhibitors of wild-type C-South African HIV-protease.
    Makatini MM; Petzold K; Sriharsha SN; Soliman ME; Honarparvar B; Arvidsson PI; Sayed Y; Govender P; Maguire GE; Kruger HG; Govender T
    Bioorg Med Chem Lett; 2011 Apr; 21(8):2274-7. PubMed ID: 21429747
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conformational flexibility in the flap domains of ligand-free HIV protease.
    Heaslet H; Rosenfeld R; Giffin M; Lin YC; Tam K; Torbett BE; Elder JH; McRee DE; Stout CD
    Acta Crystallogr D Biol Crystallogr; 2007 Aug; 63(Pt 8):866-75. PubMed ID: 17642513
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, asymmetric synthesis, and evaluation of pseudosymmetric sulfoximine inhibitors against HIV-1 protease.
    Lu D; Sham YY; Vince R
    Bioorg Med Chem; 2010 Mar; 18(5):2037-48. PubMed ID: 20138769
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis, and X-ray crystallographic analysis of a novel class of HIV-1 protease inhibitors.
    Ganguly AK; Alluri SS; Caroccia D; Biswas D; Wang CH; Kang E; Zhang Y; McPhail AT; Carroll SS; Burlein C; Munshi V; Orth P; Strickland C
    J Med Chem; 2011 Oct; 54(20):7176-83. PubMed ID: 21916489
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peptidomimetic therapeutic agents targeting the protease enzyme of the human immunodeficiency virus and hepatitis C virus.
    Tsantrizos YS
    Acc Chem Res; 2008 Oct; 41(10):1252-63. PubMed ID: 18681464
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV protease inhibitors.
    Winslow DL; Otto MJ
    AIDS; 1995; 9 Suppl A():S183-92. PubMed ID: 8819585
    [No Abstract]   [Full Text] [Related]  

  • 18. Left-handed comments.
    Siegel JS
    Science; 1992 Nov; 258(5086):1290. PubMed ID: 1455218
    [No Abstract]   [Full Text] [Related]  

  • 19. A new class of HIV-1 protease inhibitors containing a tertiary alcohol in the transition-state mimicking scaffold.
    Ekegren JK; Unge T; Safa MZ; Wallberg H; Samuelsson B; Hallberg A
    J Med Chem; 2005 Dec; 48(25):8098-102. PubMed ID: 16335934
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design and synthesis of sulfoximine based inhibitors for HIV-1 protease.
    Raza A; Sham YY; Vince R
    Bioorg Med Chem Lett; 2008 Oct; 18(20):5406-10. PubMed ID: 18829317
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.